Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Piper Jaffray analyst Barbara Hoffman said GNE's fourth quarter earnings reflected slower growth in sales
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury